The role of Kisspeptin levels in polycystic ovary syndrome: a systematic review and meta-analysis
Polycystic ovarian syndrome (PCOS) is a complex and not fully elucidated pathology. This prevalent endocrinopathy affects patients in reproductive age, impacts on estrogen-dependent diseases, as well as in infertility. In this context, Kisspeptin (KP) may be considered a potential biomarker for PCOS diagnosis and follow-up. Here, we aimed to verify the levels of KP in obese and non-obese patients with PCOS, their relationship with other hormones, in comparison to healthy controls.
A systematic review and meta-analysis were performed according to the PRISMA guidelines. We searched MEDLINE, EMBASE, PsycINFO, Global Health, The Cochrane Library, Health Technology Assessment Database, and Web of Science for eligible studies. A random effects model meta-analysis of standardized mean difference (SMD) was conducted and the I2 was used to assess heterogeneity. Meta-regression was conducted through mixed-effects model.
A total of 12 studies were included, comprising 660 PCOS patients and 600 controls. The KP levels were lower in the control group (0.76: 0.17–1.35; 95% CI). In the subgroup analyses, patients were divided in non-overweight/obese (BMI < 25) and overweight/obese (BMI ≥ 25) groups. The meta-regression revealed a difference between the obese and non-obese groups (z = 2.81; p = 0.0050).
PCOS patients showed higher KP levels than control, and obese non-PCOS patients also showed altered KP levels. All studies had poor descriptions of sample collection, pre-analytical and analytical procedures, which is critical considering structural characteristics of the KP molecule.
KeywordsPolycystic ovary syndrome Kisspeptins Human fertility Meta-analysis Obesity
Dr. Bianca Bianco for the support in the manuscript preparation.
NP Assis Rodrigues: design of the study, literature review, data collection, data analysis and manuscript writing; AS Laganà: data analysis, manuscript writing and editing; V Zaia: data collection, data analysis and review of the manuscript; A Vitagliano: data analysis and review of the manuscript; CP Barbosa: review of the manuscript; R Oliveira: data analysis, review and manuscript writing; CM Trevisan: data collection, data analysis and review of the manuscript; E Montagna: design of the study, literature review, data analysis and manuscript writing/review. All authors read and approved the final version of the manuscript.
Compliance with ethical standards
Conflict of interest
The authors have no conflicts of interest to disclose.
- 4.Mani H, Levy MJ, Davies MJ, Morris DH, Gray LJ, Bankart J, Blackledge H, Khunti K, Howlett TA (2013) Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clin Endocrinol (Oxf) 78:926–934. https://doi.org/10.1111/cen.12068 CrossRefGoogle Scholar
- 5.Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF (2006) Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 91:4237–4245. https://doi.org/10.1210/jc.2006-0178 CrossRefPubMedGoogle Scholar
- 6.Palomba S, Falbo A, Russo T, Tolino A, Orio F, Zullo F (2010) Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes. Fertil Steril 94:1805–1811. https://doi.org/10.1016/j.fertnstert.2009.10.043 CrossRefPubMedGoogle Scholar
- 8.Matsuzaki T, Tungalagsuvd A, Takeshi I, Munkhzaya M, Yanagihara R, Tokui T, Yano K, Mayila Y, Kato T, Kuwahara A, Matsui S, Irahara M (2017) Kisspeptin mRNA expression is increased in the posterior hypothalamus in the rat model of polycystic ovary syndrome. Endocr J 64:7–14. https://doi.org/10.1507/endocrj.EJ16-0282 CrossRefPubMedGoogle Scholar
- 9.Albalawi FS, Daghestani MH, Daghestani MH, Eldali A, Warsy AS (2018) rs4889 polymorphism in KISS1 gene, its effect on polycystic ovary syndrome development and anthropometric and hormonal parameters in Saudi women. J Biomed Sci 25:50. https://doi.org/10.1186/s12929-018-0452-2 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, PRISMA-P Group (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 350:g7647. https://doi.org/10.1136/bmj.g7647 CrossRefGoogle Scholar
- 13.National Center for Biotechnology Information. Available at https://pubchem.ncbi.nlm.nih.gov/compound/71306396. Accessed 27 Feb 2019
- 15.Wells G, Shea B, O’Connell D, Peterson G, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 27 Feb 2019
- 18.Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, Geleijnse JM, Rauch B, Ness A, Galan P, Chew EY, Bosch J, Collins R, Lewington S, Armitage J, Clarke R, Omega-3 Treatment Trialists’ Collaboration (2018) Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol 3:225–234. https://doi.org/10.1001/jamacardio.2017.5205 CrossRefPubMedGoogle Scholar
- 20.Baujat B, Mahé C, Pignon J-P, Hill C (2002) A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials: graphical method for exploring heterogeneity in meta-analyses. Stat Med 21:2641–2652. https://doi.org/10.1002/sim.1221 CrossRefPubMedGoogle Scholar
- 24.Branavan U, Muneeswaran K, Wijesundera WSS, Senanayake A, Chandrasekharan NV, Wijeyaratne CN (2019) Association of KISS1 and GPR54 gene polymorphisms with polycystic ovary syndrome among sri lankan women. Biomed Res Int 2019:6235680. https://doi.org/10.1155/2019/6235680 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Panidis D, Rousso D, Koliakos G, Kourtis A, Katsikis I, Farmakiotis D, Votsi E, Diamantikandarakis E (2006) Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome. Fertil Steril 85:1778–1783. https://doi.org/10.1016/j.fertnstert.2005.11.044 CrossRefPubMedGoogle Scholar
- 29.Yilmaz SA, Kerimoglu OS, Pekin AT, Incesu F, Dogan NU, Celik C, Unlu A (2014) Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 180:56–60. https://doi.org/10.1016/j.ejogrb.2014.06.004 CrossRefPubMedGoogle Scholar
- 31.Nyagolova PV, Mitkov MD, Orbetzova MM, Terzieva DD (2016) Kisspeptin and galanin-like peptide (galp) levels in women with polycystic ovary syndrome. Int J Pharmaceut Med Res 4:6–12Google Scholar
- 36.Cela V, Obino MER, Alberga Y, Pinelli S, Sergiampietri C, Casarosa E, Simi G, Papini F, Artini PG (2018) Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes. Gynecol Endocrinol 34(6):518–523. https://doi.org/10.1080/09513590.2017.1412429 CrossRefPubMedGoogle Scholar
- 43.Kolodziejski PA, Pruszynska-Oszmalek E, Korek E, Sassek M, Szczepankiewicz D, Kaczmarek P, Nogowski L, Mackowiak P, Nowak KW, Krauss H, Strowski MZ (2018) Serum levels of spexin and kisspeptin negatively correlate with obesity and insulin resistance in women. Physiol Res 67:45–56. https://doi.org/10.33549/physiolres.933467 CrossRefPubMedGoogle Scholar
- 45.Decourt C, Robert V, Anger K, Galibert M, Madinier J-B, Liu X, Dardente H, Lomet D, Delmas AF, Caraty A, Herbison AE, Anderson GM, Aucagne V, Beltramo M (2016) A synthetic kisspeptin analog that triggers ovulation and advances puberty. Sci Rep 6:26908. https://doi.org/10.1038/srep26908 CrossRefPubMedPubMedCentralGoogle Scholar